A new study shows that pregnancy and breastfeeding could change the way the body reacts to conventional lupus treatment in women due to imbalances in the gut bacterial community, or dysbiosis. The research was undertaken to understand the higher risk of severe flares and help women with lupus experience healthy pregnancies and successful outcomes, by improving therapeutic approaches.
A new study published in the journal Arthritis & Rheumatology finds there may be a genetic explanation for the development of systemic lupus erythematosus (SLE) in African American women.
The study, published on August 20, points to epigenetic changes near interferon-regulated genes early in B cell development. These changes are a “hallmark” of SLE development in African American women, the authors wrote.
“We have identified an aberrant epigenetic signature that developed early in B cell development in African American patients. This observation is consistent with recently published work which identified a SLE-specific epigenetic signature present in the resting naïve B cell stage that persists throughout development in a cohort of Africa American females,” wrote the authors who were led by Devin Absher, Ph.D., of the HudsonAlpha Institute for Biotechnology in Alabama.
Oklahoma Medical Research Foundation (OMRF) scientists have discovered that the Epstein-Barr virus may be a possible trigger for the development of lupus in at-risk individuals.
Scientists have long known lupus has a strong genetic component, but there also must be environmental triggers to activate the disease.
Autoantibodies targeting certain regulatory RNAs — molecules that serve as the template for protein production — in the brains of lupus patients are unique to these people and involved in neuropsychiatric symptoms of the disease, a study reports.
The study, “Neuronal BC RNA transport impairments caused by systemic lupus erythematosus autoantibodies,” was published in the Journal of Neuroscience.
In a new study, researchers looked at whether treatments targeting B-cell activating factor (BAFF) have an impact on human B-cells, as previous studies have suggested. B-cells are responsible for creating antibodies, including autoantibodies, and are thought to play a role in the development and progression of autoimmune diseases.
A breakthrough study by a SUNY Downstate Health Sciences University research team has identified a specific antibody target implicated in neuropsychiatric symptoms of lupus. These symptoms, including cognitive impairment, mood disorders, seizures, headaches and psychosis, are among the most prevalent manifestations of the disease and occur in as many as 80% of adults and 95% of children with lupus.
Individuals were asked whether they had tattoos or not by the experts in order to ascertain the safety of tattoos in individuals with systemic lupus erythematosus (SLE).
Twenty-eight patients (19%, 26 women, median age 33 (25–42) years, 65 tattoos in total) had ≥1 tattoo.The characteristics of the tattoos and the immediate complications were investigated and compared with those of a matched control group.
Researchers have discovered that blood clotting proteins in urine can act as biomarkers in patients with systemic lupus erythematosus (SLE), especially those with lupus nephritis.
The team of researchers at the University of Houston found that blood clotting proteins, both the ones that promote blood clotting (prothrombic) and those that disperse them (thrombolytic) are elevated in the urine of patients with lupus nephritis (LN).
Individuals with systemic lupus erythematosus (SLE) who have primary total hip arthroplasty (THA) are at higher risk for implant infection, discharge to an inpatient facility, more expensive hospital bills, and increased blood transfusions than people without SLE, according to a study recently published in Lupus.
In a study published in a recent issue of Arthritis & Rheumatology, investigators found that patients with lupus nephritis were far more likely to break a bone than patients who do not have lupus.
“Patients with lupus nephritis may be at particularly high risk of fracture due to secondary or tertiary hyperparathyroidism and vitamin D deficiency,” said study author Sara Tedeschi, M.D., MPH, a rheumatology fellow at Brigham and Women’s Hospital.
The Lupus Research Alliance shared positive topline results from a Phase 2 clinical study of a potential new treatment for proliferative lupus nephritis, the most severe form of kidney damage caused by lupus. Genentech, a member of the Roche Group, reported that at one year their drug Gazyva® (obinutuzumab) helped more patients achieve a complete response to treatment when added to standard of care with either mycophenolate mofetil or mycophenolic acid plus corticosteroids than those receiving standard of care alone.
Researchers in Dr. Leona Gilbert's research group at the University of Jyväskylä have proposed a novel mechanism for how a common viral infection could lead to an autoimmune disease. Dr. Gilbert's team demonstrated for the first time how viral components triggered cellular and ultimately tissue damage in mice, thus, providing an answer to a missing link between an infection and autoimmunity.
Hydroxychloroquine (Plaquenil®) is the most prescribed medication in the treatment of lupus and has numerous benefits including prevention of flares, prolonged survival, and other positive outcomes. Medication non-adherence is reported in up to 80% of people with lupus and is associated with reduced health outcomes.